The mechanisms underlying the unique pharmacodynamics of nateglinide

Diabetologia

Volumn 46, Issue SUPPL. 1, 2003, Pages

  Hu, S ^a   Boettcher, B R ^a   Dunning, B E ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Impaired glucose tolerance; Insulin secretion; Insulin secretory responses; Postprandial hyperglycaemia; Sulphonylureas; Type 2 diabetes

Indexed keywords

4 [[2 (1 PIPERIDYL)BENZHYDRYL]CARBAMOYLMETHYL]BENZOIC ACID; ADENOSINE TRIPHOSPHATE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; MEGLITINIDE; NATEGLINIDE; PHENYLALANINE DERIVATIVE; POTASSIUM CHANNEL; REPAGLINIDE; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR; TOLBUTAMIDE;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; INTERNALIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHARMACODYNAMICS; POSTPRANDIAL STATE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0038416010     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-0935-1     Document Type: Article

References (39)

1. Tuomilehto J, Del Prato S (2001) Mealtime glucose regulation in Type 2 diabetes. Int J Clin Pract 55:380-383
2. Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of Type 2 diabetes mellitus. J Clin Invest 104:787-794
3. Kikuchi M (1996) Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diabet Med 13:S151-S155
4. ATP channels. Annu Rev Physiol 60:667-687
5. ATP channels. Physiol Rev 78:227-245
6. + channels in pancreatic beta-cells. Nature 311:271-273
7. Dunne MJ, Petersen OH (1991) Potassium selective ion channels in insulin-secreting cells: physiology, pharmacology and their role in stimulus-secretion coupling. Biochim Biophys Acta 1071:67-82
8. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ (1995) Insulinotropic action of meglitinide analogs: concentration-response relationship and nutrient dependency. Pharm Res 32:111-114
9. Henquin JC, Garrino MG, Nenquin M (1987) Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety of glibenclamide: structural requirements and cellular mechanisms. Eur J Pharmacol 141:243-251
10. Ribes G, Trimble ER, Blayac JP, Wollheim CB, Puech R, Loubatieres-Mariani M-M (1981) Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog. Diabetologia 20:501-505
11. Zunkler BJ, Lenzen S, Manner K, Panten U, Trube G (1988) Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic beta-cells. Naunyn Schmiedebergs Arch Pharmacol 337:225-230
12. Brown GR, Foubister AJ (1984) Receptor binding sites of hypoglycemic sulfonylureas and related [(acylamino)alkyl] benzoic acids. J Med Chem 27:79-81
13. Grell W, Hurnaus R, Griss G et al. (1998) Repaglinide and related hypoglycemic benzoic acid derivatives. J Med Chem 41:5219-5246
14. Shinkai H, Toi K, Kumashiro I et al. (1988) N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents. J Med Chem 31:2092-2097
15. Shinkai H, Nishikawa M, Sato Y et al. (1989) N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2. J Med Chem 32:1436-1441
16. Pierluissi J, Navas FO, Ashcroft SJ (1986) Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia 29:119-121
17. Hu S, Wang S, Fanelli B et al. (2000) Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 293:444-452
18. Ronner P, Hang TL, Kraebber MJ, Higgins TJ (1992) Effect of the hypoglycaemic drug (-)-AZ-DF-265 on ATP-sensitive potassium channels in rat pancreatic beta-cells. Br J Pharmacol 106:250-255
19. McPherson GA (1989) A mathematical approach to receptor characterization. In: Williams M, Glennon RA, Timmermans PB (eds) Marcel Dekker, New York, pp 47-84
20. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391:85-100
21. Akiyoshi M, Kakei M, Nakazaki M, Tanaka H (1995) A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta-cells. Am J Physiol 268:E185-E193
22. ATP channels in β-cells underlies its unique insulinotropic action. Eup J Pharmacol 442:163-171
23. Tsukuda K, Sakurada M, Niki I, Oka Y, Kikuchi M (1998) Insulin secretion from isolated rat islets induced by the novel hypoglycemic agent A-4166, a derivative of D-phenylalanine. Horm Metab Res 30:42-49
24. Sato Y, Nishikawa M, Shinkai H, Sukegawa E (1991) Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 12:53-59
25. 3H-glibenclamide in pancreatic islet cells. Diabetologia 29:259-261
26. Marynissen G, Smets G, Kloppel G, Gerlache L, Malaisse WJ (1992) Internalization of glimepiride and glibenclamide in the pancreatic B-cell. Acta Diabetol 29:113-114
27. 14C-labelled A-4166 in pancreatic islets. Acta Diabetol 33:298-300
28. Fujitani S, Ikenoue T, Akiyoshi M, Maki T, Yada T (1996) Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas. Metabolism 45:184-189
29. Hirose H, Maruyama H, Seto Y et al. (1995) Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide. Pharmacology 50:175-181
30. Leclercq-Meyer V, Ladriere L, Fuhlendorff J, Malaisse WJ (1997) Stimulation of insulin and somatostatin release by two meglitinide analogs. Endocrine 7:311-317
31. Morimoto S, Mokuda O, Sakamoto Y (1998) AY-4166 increases the sensitivity of insulin secretion to glucose in isolated perfused rat pancreas. Horm Metab Res 30:77-79
32. Seto Y, Fujita H, Dan K, Fujita T, Kato R (1995) Stimulating activity of A-4166 on insulin release in in situ hamster pancreatic perfusion. Pharmacology 51:245-253
33. Souza CJ de, Russo P, Lozito R, Dunning BE (2001) Differential effects of short and long duration insulinotropic agents on meal related glucose excursions. Diabetes Obes Metab 3:73-84
34. Dunning BE, Deacon R, Gutierrez C, Paladini S, Valentin MA, Foley JE (2002) Pharmacological restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia. Diabetologia 46 [Suppl 1]:M22-M29
35. Hollander PA, Schwartz SL, Gatlin MR et al. (2001) Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24:983-988
36. Kalbag JB, Walter YH, Nedelman JR, McLeod JF (2001) Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care 24:73-77
37. Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF (2000) Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:1081-1086
38. Souza CJ de, Gagen K, Chen W, Dragonas N (2001) Early insulin release effectively improves glucose tolerance: studies in two rodent models of Type 2 diabetes mellitus. Diabetes Obes Metab 3:85-94
39. Shinkai H, Sato Y (1990) Hypoglycaemic action of phenylalanine derivatives. In: Bailey CJ, Flatt PR (eds) Smith-Gordon/Nishimura, London, pp 249-254